These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. Lai-Kwon J; Khoo C; Lo S; Milne D; Mohamed M; Raleigh J; Smith K; Lisy K; Sandhu S; Jefford M J Cancer Surviv; 2019 Aug; 13(4):503-511. PubMed ID: 31165342 [TBL] [Abstract][Full Text] [Related]
15. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540 [TBL] [Abstract][Full Text] [Related]
16. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342 [TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620 [TBL] [Abstract][Full Text] [Related]
18. Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review. Lai-Kwon J; Inderjeeth AJ; Lisy K; Sandhu S; Rutherford C; Jefford M Eur J Cancer; 2023 May; 184():83-105. PubMed ID: 36907021 [TBL] [Abstract][Full Text] [Related]
19. Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma-A Real World Single-Center Analysis. Hoffmann M; Hayoz S; Özdemir BC Biology (Basel); 2022 Mar; 11(3):. PubMed ID: 35336796 [TBL] [Abstract][Full Text] [Related]